Cost implications of implementation of pathogen-inactivated platelets

Jeffrey McCullough, Dennis Goldfinger, Jed Gorlin, William Riley, Harpreet Sandhu, Christopher Stowell, Dawn Ward, Mary Clay, Shelley Pulkrabek, Vera Chrebtow, Adonis Stassinopoulos

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

BACKGROUND Pathogen inactivation (PI) is a new approach to blood safety that may introduce additional costs. This study identifies costs that could be eliminated, thereby mitigating the financial impact. STUDY DESIGN AND METHODS Cost information was obtained from five institutions on tests and procedures (e.g., irradiation) currently performed, that could be eliminated. The impact of increased platelet (PLT) availability due to fewer testing losses, earlier entry into inventory, and fewer outdates with a 7-day shelf life were also estimated. Additional estimates include costs associated with managing 1) special requests and 2) test results, 3) quality control and proficiency testing, 4) equipment acquisition and maintenance, 5) replacement of units lost to positive tests, 6) seasonal or geographic testing, and 7) health department interactions. RESULTS All costs are mean values per apheresis PLT unit in USD ($/unit). The estimated test costs that could be eliminated are $71.76/unit and a decrease in transfusion reactions corresponds to $2.70/unit. Avoiding new tests (e.g., Babesia and dengue) amounts to $41.80/unit. Elimination of irradiation saves $8.50/unit, while decreased outdating with 7-day storage can be amortized to $16.89/unit. Total potential costs saved with PI is $141.65/unit. Costs are influenced by a variety of factors specific to institutions such as testing practices and the location in which such costs are incurred and careful analysis should be performed. Additional benefits, not quantified, include retention of some currently deferred donors and scheduling flexibility due to 7-day storage. CONCLUSIONS While PI implementation will result in additional costs, there are also potential offsetting cost reductions, especially after 7-day storage licensing.

Original languageEnglish (US)
Pages (from-to)2312-2320
Number of pages9
JournalTransfusion
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Blood Platelets
Costs and Cost Analysis
Blood Safety
Babesia
Equipment and Supplies
Blood Component Removal
Dengue
Licensure
Quality Control
Maintenance
Health

ASJC Scopus subject areas

  • Hematology
  • Immunology
  • Immunology and Allergy

Cite this

McCullough, J., Goldfinger, D., Gorlin, J., Riley, W., Sandhu, H., Stowell, C., ... Stassinopoulos, A. (2015). Cost implications of implementation of pathogen-inactivated platelets. Transfusion, 55(10), 2312-2320. https://doi.org/10.1111/trf.13149

Cost implications of implementation of pathogen-inactivated platelets. / McCullough, Jeffrey; Goldfinger, Dennis; Gorlin, Jed; Riley, William; Sandhu, Harpreet; Stowell, Christopher; Ward, Dawn; Clay, Mary; Pulkrabek, Shelley; Chrebtow, Vera; Stassinopoulos, Adonis.

In: Transfusion, Vol. 55, No. 10, 01.10.2015, p. 2312-2320.

Research output: Contribution to journalArticle

McCullough, J, Goldfinger, D, Gorlin, J, Riley, W, Sandhu, H, Stowell, C, Ward, D, Clay, M, Pulkrabek, S, Chrebtow, V & Stassinopoulos, A 2015, 'Cost implications of implementation of pathogen-inactivated platelets', Transfusion, vol. 55, no. 10, pp. 2312-2320. https://doi.org/10.1111/trf.13149
McCullough J, Goldfinger D, Gorlin J, Riley W, Sandhu H, Stowell C et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion. 2015 Oct 1;55(10):2312-2320. https://doi.org/10.1111/trf.13149
McCullough, Jeffrey ; Goldfinger, Dennis ; Gorlin, Jed ; Riley, William ; Sandhu, Harpreet ; Stowell, Christopher ; Ward, Dawn ; Clay, Mary ; Pulkrabek, Shelley ; Chrebtow, Vera ; Stassinopoulos, Adonis. / Cost implications of implementation of pathogen-inactivated platelets. In: Transfusion. 2015 ; Vol. 55, No. 10. pp. 2312-2320.
@article{dc5c2ea0338348fa848b2f729845efdd,
title = "Cost implications of implementation of pathogen-inactivated platelets",
abstract = "BACKGROUND Pathogen inactivation (PI) is a new approach to blood safety that may introduce additional costs. This study identifies costs that could be eliminated, thereby mitigating the financial impact. STUDY DESIGN AND METHODS Cost information was obtained from five institutions on tests and procedures (e.g., irradiation) currently performed, that could be eliminated. The impact of increased platelet (PLT) availability due to fewer testing losses, earlier entry into inventory, and fewer outdates with a 7-day shelf life were also estimated. Additional estimates include costs associated with managing 1) special requests and 2) test results, 3) quality control and proficiency testing, 4) equipment acquisition and maintenance, 5) replacement of units lost to positive tests, 6) seasonal or geographic testing, and 7) health department interactions. RESULTS All costs are mean values per apheresis PLT unit in USD ($/unit). The estimated test costs that could be eliminated are $71.76/unit and a decrease in transfusion reactions corresponds to $2.70/unit. Avoiding new tests (e.g., Babesia and dengue) amounts to $41.80/unit. Elimination of irradiation saves $8.50/unit, while decreased outdating with 7-day storage can be amortized to $16.89/unit. Total potential costs saved with PI is $141.65/unit. Costs are influenced by a variety of factors specific to institutions such as testing practices and the location in which such costs are incurred and careful analysis should be performed. Additional benefits, not quantified, include retention of some currently deferred donors and scheduling flexibility due to 7-day storage. CONCLUSIONS While PI implementation will result in additional costs, there are also potential offsetting cost reductions, especially after 7-day storage licensing.",
author = "Jeffrey McCullough and Dennis Goldfinger and Jed Gorlin and William Riley and Harpreet Sandhu and Christopher Stowell and Dawn Ward and Mary Clay and Shelley Pulkrabek and Vera Chrebtow and Adonis Stassinopoulos",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/trf.13149",
language = "English (US)",
volume = "55",
pages = "2312--2320",
journal = "Transfusion",
issn = "0041-1132",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Cost implications of implementation of pathogen-inactivated platelets

AU - McCullough, Jeffrey

AU - Goldfinger, Dennis

AU - Gorlin, Jed

AU - Riley, William

AU - Sandhu, Harpreet

AU - Stowell, Christopher

AU - Ward, Dawn

AU - Clay, Mary

AU - Pulkrabek, Shelley

AU - Chrebtow, Vera

AU - Stassinopoulos, Adonis

PY - 2015/10/1

Y1 - 2015/10/1

N2 - BACKGROUND Pathogen inactivation (PI) is a new approach to blood safety that may introduce additional costs. This study identifies costs that could be eliminated, thereby mitigating the financial impact. STUDY DESIGN AND METHODS Cost information was obtained from five institutions on tests and procedures (e.g., irradiation) currently performed, that could be eliminated. The impact of increased platelet (PLT) availability due to fewer testing losses, earlier entry into inventory, and fewer outdates with a 7-day shelf life were also estimated. Additional estimates include costs associated with managing 1) special requests and 2) test results, 3) quality control and proficiency testing, 4) equipment acquisition and maintenance, 5) replacement of units lost to positive tests, 6) seasonal or geographic testing, and 7) health department interactions. RESULTS All costs are mean values per apheresis PLT unit in USD ($/unit). The estimated test costs that could be eliminated are $71.76/unit and a decrease in transfusion reactions corresponds to $2.70/unit. Avoiding new tests (e.g., Babesia and dengue) amounts to $41.80/unit. Elimination of irradiation saves $8.50/unit, while decreased outdating with 7-day storage can be amortized to $16.89/unit. Total potential costs saved with PI is $141.65/unit. Costs are influenced by a variety of factors specific to institutions such as testing practices and the location in which such costs are incurred and careful analysis should be performed. Additional benefits, not quantified, include retention of some currently deferred donors and scheduling flexibility due to 7-day storage. CONCLUSIONS While PI implementation will result in additional costs, there are also potential offsetting cost reductions, especially after 7-day storage licensing.

AB - BACKGROUND Pathogen inactivation (PI) is a new approach to blood safety that may introduce additional costs. This study identifies costs that could be eliminated, thereby mitigating the financial impact. STUDY DESIGN AND METHODS Cost information was obtained from five institutions on tests and procedures (e.g., irradiation) currently performed, that could be eliminated. The impact of increased platelet (PLT) availability due to fewer testing losses, earlier entry into inventory, and fewer outdates with a 7-day shelf life were also estimated. Additional estimates include costs associated with managing 1) special requests and 2) test results, 3) quality control and proficiency testing, 4) equipment acquisition and maintenance, 5) replacement of units lost to positive tests, 6) seasonal or geographic testing, and 7) health department interactions. RESULTS All costs are mean values per apheresis PLT unit in USD ($/unit). The estimated test costs that could be eliminated are $71.76/unit and a decrease in transfusion reactions corresponds to $2.70/unit. Avoiding new tests (e.g., Babesia and dengue) amounts to $41.80/unit. Elimination of irradiation saves $8.50/unit, while decreased outdating with 7-day storage can be amortized to $16.89/unit. Total potential costs saved with PI is $141.65/unit. Costs are influenced by a variety of factors specific to institutions such as testing practices and the location in which such costs are incurred and careful analysis should be performed. Additional benefits, not quantified, include retention of some currently deferred donors and scheduling flexibility due to 7-day storage. CONCLUSIONS While PI implementation will result in additional costs, there are also potential offsetting cost reductions, especially after 7-day storage licensing.

UR - http://www.scopus.com/inward/record.url?scp=84943818347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943818347&partnerID=8YFLogxK

U2 - 10.1111/trf.13149

DO - 10.1111/trf.13149

M3 - Article

C2 - 25989465

AN - SCOPUS:84943818347

VL - 55

SP - 2312

EP - 2320

JO - Transfusion

JF - Transfusion

SN - 0041-1132

IS - 10

ER -